

1 2 3		Washington Vaccine Association Operations Committee Meeting April 28, 2022; 12:30-1:30 p.m. PT				
4 5		I. Attendance. Participating in all or part of the meeting by telephone were the following individuals:				
6		i. Atten	uance. Farticipating in an or part	of the filee	ting by telephone were the following individuals.	
7		<u>Members</u>		18		
8		Walter Kuiee, Regence		19	Helms & Company, Inc.	
9		Jennifer Simonsen, Kaiser		20	Patrick Miller, MPH, Administrative Director	
10		Tracey Cardillo, Cigna		21	Lisa White, JD, Customer and Financial Support	
11		Michelle Baker, Zenith American Solutions		22	Specialist	
12		Sue Bride, Premera		23	Ashley Ithal, MPH, Project Support Leader	
13		Cathy Falanga, Aetna		24	· · · · · · · · · · · · · · · · · · ·	
14		Nicole Carroll, UnitedHealthcare		25	Members of the Public	
15				26	Delphia May, Cigna	
16		<u>WVA</u>		27	Erika Cliett, UnitedHealthcare	
17		Julia G. Zell, E	sq., Executive Director, Chair	28	Tiffany Miller, UnitedHealthcare	
29			•		•	
30	I.	Summary of Actions Taken and/or Recommended				

31 32

33

Actions Taken (votes adopted)

- To approve October 28, 2021, meeting minutes. i.
- ii. To approve the 2022-2023 WVA Vaccine Grid.

34 35 36

II. Welcome and Introductions

37 38

At 12:32 p.m., Ms. Zell called the meeting to order and provided a notice of recording. Mr. Miller introduced the attending staff members from Helms.

39 40 41

III. **Voting Items**

42 43

Ms. Zell asked for a motion to approve the October 28, 2021, meeting minutes. Ms. Cardillo, Ms. Comer, and Ms. Simonsen commented that the spelling of their names be corrected. There being no other questions or comments, the following item was put to a vote:

45 46

44

Upon motion duly made and seconded, it was unanimously

47 48 49

VOTED: To approve October 28, 2021, meeting minutes with the requested corrections.

50 51

IV. 2022-2023 WVA Vaccine Grid

52 53

54

55

56

57

58

59

Mr. Miller provided an overview of the 2022-2023 WVA Vaccine Grid and process for development. He noted that no new CPT codes were added this year, nor changes in the assessment amounts, but that there are some changes to National Drug Codes (NDC). Related to Department of Health (DOH) projections, the DOH will recalculate the VFC fund source split this summer; any adjustment could have a significant impact on cash. Another potential factor in cash considerations centers upon the potential inclusion of the COVID vaccine in the Childhood Vaccine Program (CVP). Mr. Miller also noted that it is unclear when the federal government will cease to pay for COVID-19 vaccines, but when that does occur the WVA and DOH will need to review how these vaccines get paid for within the WVA program.

60 61

62 Ms. Zell asked for a motion to approve the 2022-2023 WVA Vaccine Grid. There being no questions or comments, 63 the following item was put to a vote:

1 2

Upon motion duly made and seconded, it was unanimously

3 4

VOTED: To approve the 2022-2023 WVA Vaccine Grid.

5 6

Mr. Miller stated that the updated grid will be posted to the WVA website by tomorrow, and then distributed electronically and physically mailed to providers, payers, and partners over the next four weeks.

7 8 9

V. **Operations Updates**

10 11

12

13

Payer and Provider Compliance. Ms. Zell described current payer compliance efforts. She noted that feedback from payers has driven the effort to update the WVA compliance materials. Mr. Miller provided an update on the progress being made with the WVA's graphic designer on the revised Payer Billing Compliance Guide, which will be included as a supplemental document in the annual assessment grid mailing.

14 15 16

Ms. Zell raised to topic of a future an annual payer certification/verification process. Discussion ensued within the Committee about the helpfulness of this type of process. The WVA will continue to evaluate its potential.

17 18 19

20

21

22

23

Ms. Zell provided a provider compliance effort update. She explained that historically the WVA has not had a direct relationship with providers; however, in the last two years it has become more apparent that there could be efficiencies in time and effort by having the WVA team more directly involved in provider education and compliance. Ms. Zell described the most recent efforts between the WVA team and the DOH to support providers, including an informational webinar as well as updating the WVA Provider Billing Guide with an expanded compliance checklist. Mr. Miller added that as new provider practices are onboarded, new processes are in place for outreach to the WVA team to ensure billing guidelines are understood by the provider practice.

28

29

30

31

Key Performance Indicators (KPIs). Mr. Miller provided an overview of the WVA KPIs which are generated and sent to the Board monthly. He mentioned that the DOH provides remittance projections twice a year, in April and November, and that actuals are reviewed monthly. Mr. Miller reported that vaccines are costing more but that assessment rates have been kept level due to the ability to leverage cash reserves to absorb increases. Ms. Zell asked the committee members if there were other indicators that could be added, and the committee did not make any recommended additions.

32 33 34

35

VI. Closing

Ms. Zell thanked everyone for their input and guidance today, and the meeting was adjourned at 1:14 pm PT.